FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 354:2387-2389 June 1, 2006 Number 22 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Ropper, A. H. Related Article by Polman, C. H. Related Article by Rudick, R. A. Related Article by Yousry, T. A. PubMed Citation

To the Editor: As Ropper pointed out in his editorial (March 2 issue),¹ the three articles on the use of natalizumab in that issue of the Journal are pivotal, but his conclusion that natalizumab is "a potent treatment for multiple sclerosis" may be too sanguine. The similar entry criteria, treatment, and methods of analysis permit clinically useful conclusions to be drawn from the placebo-controlled study of natalizumab by Polman et al.² and the study of natalizumab plus interferon beta by Rudick et al.³ A comparison of Figure 2 in both studies is illustrative. In the study by Polman et al., . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.